{
  "docId": "019de076-57a4-77f9-94ab-9b0feede6704",
  "docSlug": "a14e4b0042ed971c9f1fd15d53e19956",
  "documentTitle": "MaxCyte | Results Presentation Deck | 25 slides",
  "authorId": "maxcyte",
  "authorName": "MaxCyte",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 25,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "propose_solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-57a4-77f9-94ab-9b0feede6704/19",
  "deckHref": "/decks/019de076-57a4-77f9-94ab-9b0feede6704",
  "deckJsonHref": "/decks/019de076-57a4-77f9-94ab-9b0feede6704.json",
  "deckAnchorHref": "/decks/019de076-57a4-77f9-94ab-9b0feede6704#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.21,
        "x": 0.21,
        "y": 0.06
      },
      "kind": "image",
      "text": "VLx device image",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "decb5520-3606-44a1-9e1a-113e41ae4350",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.44,
        "x": 0.516,
        "y": 0.395
      },
      "kind": "list",
      "text": "Traditional Approach: The process begins with transiently expressing product using transfection early on in Discovery phase followed by establishing a stable cell line process (industry standard ~6+ months) in preclinical development and beyond; Stable cell line development process is lengthy, cumbersome, complex, and costly, and significantly contributes to time to IND filing",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3972d791-5fab-4baf-848d-0182de39ffcb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.44,
        "x": 0.516,
        "y": 0.68
      },
      "kind": "list",
      "text": "VLx-Enabled Approach: Expedites the production of the required amount of product (multi-gram quantify) to conduct in-vivo and in-vitro studies for IND filing in only ~4-6 weeks; This concept introduces a new “speed to product selection” strategy, enabling investment in stable cell line development only for promising/successful drug candidates",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "503e5f92-7396-4f1d-94e2-cfc149d8a2e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.44,
        "x": 0.055,
        "y": 0.535
      },
      "kind": "list",
      "text": "Transfect up to 200 billion cells in a fully closed, single-use system in less than 30 minutes; Achieve reproducible results; Bench-scale, modular equipment; Proprietary Flow Electroporation Technology; cGMP-compliant",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cfdac9c1-9ac7-4a46-b6e3-e37617de0553",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.16,
        "x": 0.18,
        "y": 0.485
      },
      "kind": "title",
      "text": "VLx Platform Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "571afede-c71f-4a48-95b9-3d798590fa6f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.042,
        "w": 0.44,
        "x": 0.516,
        "y": 0.116
      },
      "kind": "title",
      "text": "Biotherapeutic Development: Monoclonal Antibodies, Recombinant Proteins and Vaccines",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62cf335e-5932-47c2-b98b-c384567c4a02",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}